NYSEAMERICAN:IGC IGC Pharma Q3 2026 Earnings Results & Report $0.20 -0.01 (-3.62%) As of 03:09 PM Eastern This is a fair market value price provided by Massive. Learn more. IGC Pharma met analyst earnings expectations in its Q3 2026 results, released November 6, 2026. The company reported EPS of -$0.02 versus the -$0.02 consensus estimate, while revenue was $328 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 6, 2026TimeAfter Market ClosesConference Call7:00 AM ET IGC Pharma EPS ResultsActual EPS-$0.02Consensus EPS -$0.02Beat/MissMet ExpectationsOne Year Ago EPSN/AIGC Pharma Revenue ResultsActual Revenue$328 thousandExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) IGC Pharma Q3 2026 Earnings FAQ Did IGC Pharma beat earnings estimates for Q3 2026? IGC Pharma (NYSEAMERICAN:IGC) reported earnings of -$0.02 per share for Q3 2026, matching the consensus estimate of -$0.02. The report was announced on Friday, November 6, 2026. What was IGC Pharma's revenue for Q3 2026? IGC Pharma reported revenue of $328 thousand for Q3 2026. IGC Pharma Earnings HeadlinesIGC Pharma Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 9 at 5:54 PM | finance.yahoo.comIGC Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 7 at 10:07 AM | marketscreener.comMI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 10 at 1:00 AM | Behind the Markets (Ad)IGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout NearsNovember 5, 2026 | finance.yahoo.com4 Low-Priced Listed Stocks: VIVS, IGC, RIME, TOPP, With Catalysts to WatchOctober 7, 2026 | marketscreener.comMIGC Pharma, Inc.: IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026September 28, 2026 | finanznachrichten.deSee More IGC Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IGC Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IGC Pharma and other key companies, straight to your email. Email Address About IGC PharmaIGC Pharma (NYSEAMERICAN:IGC) is a biotechnology company focused on developing cannabinoid-based pharmaceutical products and therapies. The company’s research programs target neurological and other health conditions, including Alzheimer’s disease, dementia-related symptoms, pain, seizures and related disorders. One of IGC Pharma’s principal development programs is IGC-AD1, an investigational cannabinoid-based therapy being studied for dementia-related agitation associated with Alzheimer’s disease. The company has also developed cannabinoid formulations and consumer products, including products previously marketed under the Hyalolex name. Its pipeline and product development activities are centered on applying cannabinoid compounds and related formulations to unmet medical needs. The company was originally established as India Globalization Capital, Inc. and historically pursued infrastructure and technology-related activities before shifting its focus toward biotechnology and cannabinoid-based therapeutics. IGC Pharma is headquartered in Bethesda, Maryland. Ram Mukunda serves as the company’s chief executive officer and has been associated with its transition into the pharmaceutical and biotechnology sector.View IGC Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles D-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Microsoft’s Neocloud Pullback Isn’t a Crack in AI DemandOklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
